Allergan’s board has told Valeant to take its takeover offer elsewhere. Modern Healthcare reports that Allergan’s board said the $54 million offer was too low, with too much shareholder risk.
CEO David Pyott told MH the fallout would have probably included a reduced R&D budget, less advertising and higher prices for Allergan products.
